|Bid||29.62 x 1000|
|Ask||31.45 x 800|
|Day's range||30.02 - 31.45|
|52-week range||12.80 - 50.54|
|Beta (5Y monthly)||1.95|
|PE ratio (TTM)||N/A|
|Earnings date||02 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.25|
ARNC, BSET, FMS, OCUL, and PTGX have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2021.
NEW YORK, September 23, 2021--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ: PTGX) on behalf of Protagonist stockholders. Our investigation concerns whether Protagonist has violated the federal securities laws and/or engaged in other unlawful business practices.
RADNOR, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (“Protagonist”). Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology platform. Protagonist’s pipe